Niki BioSolutions, Inc.
NIKIHealthcare|Biotechnology|US
$1.58
+0.08 (+5.33%)
DCF Value
$0.14
Tangible Book / Share
$187.59
Cash / Share
$46.97
Financials
Financial Snapshot
Market Cap
$128.7K
Enterprise Value
$118.7K
Revenue (TTM)
$0.00
Net Income (TTM)
-$2.3M
Cash & Investments
$3.5M
Net Cash
$10.0K
Free Cash Flow (TTM)
-$3.3M
Operating CF (TTM)
-$3.3M
Debt/Equity
0.15
Cash Runway & Burn Rate
Cash on Hand
$3.5M
Quarterly Burn
$815.9K
Monthly Burn
$272.0K
Est. Runway
~4.2 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $18.2M | $13.0M | $6.3M | $31.9M | $8.5M | $2.0M | $2.0M | $874.2K | $3.5M | $3.5M | |
| Operating Cash Flow | -$5.8M | -$10.0M | -$13.4M | -$15.9M | -$14.7M | -$12.3M | -$7.7M | -$1.2M | -$1.8M | -$3.3M | |
| Free Cash Flow | -$8.8M | -$16.1M | -$14.5M | -$16.1M | -$14.8M | -$12.5M | -$7.7M | -$1.2M | -$1.8M | -$3.3M | |
| Capital Expenditure | -$3.1M | -$6.1M | -$1.1M | -$161.3K | -$137.8K | -$186.9K | -$3.0K | $0.00 | $0.00 | -$48.00 | |
| Financing Cash Flow | $9.1M | $25.5M | -$7.3M | $12.4M | $2.8M | $6.6M | $4.1M | $0.00 | $4.4M | $4.7M |
R&D Spending
R&D (TTM)
$68.4K
R&D Intensity
—
R&D Growth vs Prior
-80.6%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $383.4K | $535.2K | $911.5K | $1.5M | $1.3M | $431.4K | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $2.5M | $3.1M | $6.9M | $11.6M | $10.9M | $9.2M | $5.2M | $1.9M | $352.9K | $68.4K | |
| R&D % of Revenue | — | 808.7% | 1296.6% | 1271.2% | 704.9% | 711.4% | 1205.0% | — | — | — | |
| SG&A | $2.9M | $6.7M | $10.8M | $7.7M | $8.0M | $8.0M | $4.4M | $1.5M | $1.6M | $2.1M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $383.4K | $535.2K | $911.5K | $1.5M | $1.3M | $431.4K | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $58.9K | $318.0K | $794.5K | $1.0M | $1.5M | $1.2M | $420.8K | $255.0K | $0.00 | $0.00 | |
| Gross Profit | -$58.9K | $65.4K | -$259.0K | -$104.0K | $81.9K | $80.1K | $10.6K | -$255.0K | $0.00 | $0.00 | |
| R&D | $2.5M | $3.1M | $6.9M | $11.6M | $10.9M | $9.2M | $5.2M | $1.9M | $352.9K | $68.4K | |
| SG&A | $2.9M | $6.7M | $10.8M | $7.7M | $8.0M | $8.0M | $4.4M | $1.5M | $1.6M | $2.1M | |
| Operating Income | -$5.7M | -$10.3M | -$18.2M | -$19.9M | -$19.2M | -$17.5M | -$10.6M | -$3.8M | -$1.8M | -$402.8K | |
| Interest Expense | $0.00 | $4.5M | $3.7M | $243.6K | $93.6K | $0.00 | $121.1K | $146.9K | $95.7K | $73.5K | |
| Pretax Income | -$2.6M | -$15.1M | -$20.1M | $4.9M | -$27.1M | -$11.5M | -$4.3M | -$4.2M | -$1.4M | -$2.1M | |
| Net Income | -$2.5M | -$14.8M | -$18.7M | $7.1M | -$25.0M | -$9.8M | -$2.8M | -$4.3M | -$1.4M | -$2.3M | |
| EPS (Diluted) | -85.00 | -531.00 | -640.00 | 200.00 | -715.00 | -275.00 | -62.00 | -78.00 | -19.00 | -33.50 | |
| EBITDA | -$2.5M | -$10.0M | -$15.1M | $6.5M | -$25.8M | -$10.0M | -$9.2M | -$3.7M | -$1.8M | -$1.5M | |
| Shares Out. (M) | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.07 | 0.07 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.2M | $12.0M | $5.2M | $3.5M | $8.1M | $1.9M | $2.0M | $874.2K | $3.5M | $3.5M | |
| Short-Term Investments | $2.0M | $1.0M | $1.1M | $28.4M | $236.6K | $102.5K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $20.3M | $28.7M | $8.0M | $33.7M | $12.7M | $7.1M | $2.5M | $959.6K | $3.6M | $3.6M | |
| Total Assets | $31.6M | $45.1M | $24.0M | $44.2M | $21.9M | $20.9M | $20.6M | $16.1M | $18.7M | $18.7M | |
| Total Current Liabilities | $1.3M | $12.2M | $2.7M | $3.9M | $4.4M | $12.5M | $2.1M | $4.3M | $4.6M | $4.6M | |
| Long-Term Debt | $0.00 | $0.00 | $6.3M | $2.0M | $0.00 | $500.0K | $3.1M | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.3M | $12.3M | $9.1M | $6.1M | $4.4M | $13.0M | $5.3M | $4.4M | $4.9M | $4.9M | |
| Stockholders' Equity | $30.2M | $33.1M | $16.4M | $41.8M | $23.6M | $15.7M | $24.8M | $21.1M | $23.2M | $23.2M | |
| Retained Earnings | -$2.5M | -$17.4M | -$37.6M | -$30.5M | -$55.5M | -$65.3M | -$68.2M | -$72.4M | -$73.8M | -$73.8M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.8M | -$10.0M | -$13.4M | -$15.9M | -$14.7M | -$12.3M | -$7.7M | -$1.2M | -$1.8M | -$3.3M | |
| Capital Expenditure | -$3.1M | -$6.1M | -$1.1M | -$161.3K | -$137.8K | -$186.9K | -$3.0K | $0.00 | $0.00 | -$48.00 | |
| Free Cash Flow | -$8.8M | -$16.1M | -$14.5M | -$16.1M | -$14.8M | -$12.5M | -$7.7M | -$1.2M | -$1.8M | -$3.3M | |
| Investing Cash Flow | $12.8M | -$6.1M | -$108.1K | $1.8M | $16.5M | $2.4M | $624.8K | $58.6K | $0.00 | $124.6K | |
| Financing Cash Flow | $9.1M | $25.5M | -$7.3M | $12.4M | $2.8M | $6.6M | $4.1M | $0.00 | $4.4M | $4.7M | |
| Issuance of Stock | $8.6M | $11.1M | $0.00 | $17.5M | $4.0M | $5.4K | $1.6M | $0.00 | $5.1M | $1.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $480.0K | $16.1M | -$7.3M | -$4.4M | -$2.0M | $6.5M | $2.5M | $0.00 | $0.00 | $3.0M | |
| Stock Based Comp. | $0.00 | $0.00 | $1.6M | $1.5M | $1.7M | $1.6M | $1.3M | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $16.1M | $9.4M | -$20.8M | -$1.7M | $4.6M | -$3.2M | -$3.0M | -$1.1M | $2.6M | $1.6M |
Dilution Tracker
Shares outstanding grew 133.2% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+133.2%
Stock Issuance (TTM)
$1.7M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.07 | 0.07 | |
| Change vs Prior % | — | -7.3% | 3.9% | 8.7% | 11.1% | 1.9% | 26.7% | 20.6% | 34.8% | 0.0% | |
| Stock Issuance | $8.6M | $11.1M | $0.00 | $17.5M | $4.0M | $5.4K | $1.6M | $0.00 | $5.1M | $1.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $1.6M | $1.5M | $1.7M | $1.6M | $1.3M | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 17.1% | -48.4% | -11.4% | 5.3% | 6.2% | 2.4% | — | — | — | |
| Operating Margin % | — | -2693.4% | -3400.4% | -2182.6% | -1245.6% | -1351.0% | -2457.5% | — | — | — | |
| Net Margin % | — | -3868.0% | -3491.8% | 775.3% | -1624.4% | -756.2% | -654.9% | — | — | — | |
| EBITDA Margin % | — | -2606.3% | -2824.8% | 713.0% | -1675.0% | -769.2% | -2138.2% | — | — | — | |
| FCF Margin % | — | -4198.7% | -2707.5% | -1765.6% | -959.1% | -965.0% | -1791.3% | — | — | — | |
| ROE % | -8.4% | -44.8% | -114.2% | 16.9% | -106.1% | -62.4% | -11.4% | -20.2% | -5.9% | -5.9% | |
| ROA % | -8.1% | -32.9% | -78.0% | 16.0% | -114.3% | -47.0% | -13.7% | -26.5% | -7.3% | -7.3% | |
| ROIC % | -18.4% | -24.0% | -85.3% | -48.0% | -107.1% | -119.2% | -56.8% | -25.1% | -10.4% | -2.3% | |
| R&D / Revenue % | — | 808.7% | 1296.6% | 1271.2% | 704.9% | 711.4% | 1205.0% | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 39.6% | 70.3% | 69.2% | -16.0% | -66.7% | -100.0% | 0.0% | |
| Gross Profit | 0.0% | 211.1% | -495.8% | 59.8% | 178.7% | -2.2% | -86.8% | -2513.4% | 100.0% | |
| Operating Income | 0.0% | -81.4% | -76.2% | -9.3% | 3.5% | 8.8% | 39.5% | 64.2% | 52.1% | |
| Net Income | 0.0% | -482.3% | -26.0% | 137.8% | -454.4% | 60.9% | 71.2% | -51.1% | 68.1% | |
| EPS (Diluted) | 0.0% | -524.7% | -20.5% | 131.3% | -457.5% | 61.5% | 77.5% | -25.8% | 75.6% | |
| Operating Cash Flow | 0.0% | -73.5% | -33.4% | -19.0% | 8.0% | 15.9% | 37.3% | 84.6% | -54.4% | |
| Free Cash Flow | 0.0% | -82.1% | 10.0% | -11.1% | 8.1% | 15.4% | 38.2% | 84.6% | -54.4% | |
| R&D Expense | 0.0% | 24.0% | 123.8% | 67.0% | -6.2% | -15.2% | -43.6% | -62.6% | -81.8% | |
| SG&A Expense | 0.0% | 134.0% | 60.1% | -28.5% | 4.1% | -0.8% | -44.6% | -66.7% | 11.3% | |
| Total Assets | 0.0% | 42.8% | -46.9% | 84.6% | -50.5% | -4.7% | -1.1% | -21.9% | 15.9% | |
| Book Value / Share | 0.0% | 16.9% | -56.4% | 139.3% | -59.2% | -56.1% | 55.0% | -36.5% | -13.1% | |
| Debt | 0.0% | 2044.8% | -37.1% | -48.7% | -93.5% | 3056.4% | -52.1% | 2.2% | 2.6% | |
| Diluted Shares | 0.0% | -7.3% | 3.9% | 8.7% | 11.1% | 1.9% | 26.7% | 20.6% | 34.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High15.15 / 84.38 / 1104.90
P/B0.01
10Y Low / Med / High0.34 / 1.84 / 28.10
EV/EBITDAAt Loss
EV/Revenue0.00
10Y Low / Med / High18.98 / 84.19 / 1100.44
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.14
Tangible Book / Share
$187.59
Cash / Share
$46.97
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -168.82 | -28.59 | -24.77 | 12.17 | -2.10 | -2.00 | -3.95 | -3.59 | -5.58 | -0.08 | |
| P/S Ratio | 0.00 | 1104.90 | 859.19 | 84.38 | 34.08 | 15.15 | 25.67 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 14.29 | 12.79 | 28.10 | 1.84 | 2.23 | 1.25 | 0.45 | 0.72 | 0.34 | 0.01 | |
| EV/EBITDA | -166.38 | -42.22 | -30.50 | 11.81 | -1.73 | -2.47 | -1.34 | -4.79 | -4.28 | -0.07 | |
| EV/Revenue | 0.00 | 1100.44 | 861.59 | 84.19 | 28.94 | 18.98 | 28.63 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-5.85
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 |
|---|---|
| Revenue | $106.8M |
| Net Income | $2.3M |
| EPS | $31.00 |
| # Analysts (EPS) | 1 |